This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Apple Pays Proview $60M to Settle iPad Dispute: Hot Trends

Stocks in this article: AAPL SNE BMY AMLN AZN

NEW YORK ( TheStreet) -- Popular searches on the Internet include Apple (AAPL) as the tech titan has shelled out $60 million in the dispute over the name of its iPad tablet.

Apple agreed to pay the settlement to Proview Technology, a maker of computer screens and LED lights in China, after mediation talks. Proview had argued that Apple did not trademark the iPad name in China, despite doing so in other countries. Apple said its international trademark on the iPad name gave the company rights to the name everywhere.

The case went to a higher court in Guangdong after Proview won in a lower court late last year. Proview was declared bankrupt during the case.

Sony (SNE) is trending as it said it will purchase cloud-gaming company Gaikai in an all-shares deal for $380 million.

Sony plans to create a new cloud-based service based on Gaikai's platform. Gaikai's platform enables users to stream games on various devices.

The deal is subject to regulatory approval. The date by which it is expected to be completed is unknown.

Just a week ago, Gaikai CEO David Perry denied there was any deal between the two companies.

Bristol-Myers Squibb (BMY) is another popular search. The company announced it will buy diabetes drugmaker Amylin Pharmaceuticals (AMLN) for $5.3 billion, or $31 a share, in cash. Including debt, the deal is valued at about $7 billion.

The deal will expand Bristol-Myers' portfolio of diabetes treatments with Amylin's products like Byetta and Bydureon.

In a follow-up deal, Bristol-Myers also will receive $3.4 billion from AstraZeneca (AZN) to develop Amylin's drugs. Bristol-Myers and AstraZeneca already collaborate on several diabetes drugs. The boards of Amylin, Bristol-Myers and AstraZeneca have approved the two deals.

Amylin rejected a previous $3.5 billion takeover bid from Bristol-Myers.

The chatter on Main Street (a.k.a. Google, Yahoo! and other search sites) is always of interest to investors on Wall Street. Thus, each day, TheStreet compiles the stories that are trending on the Web, and highlights the news that could make stocks move.

-- Written by Brittany Umar.

Brittany joined TV in November 2006 after completing a degree in Journalism and Media Studies at Rutgers College. Previously, Brittany interned at the local ABC affiliate in New York City WABC-TV 7 where she helped research and produce On Your Side, a popular consumer advocacy segment.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs